Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D07OIO
|
|||
| Former ID |
DND000017
|
|||
| Drug Name |
AZD-2461
|
|||
| Synonyms |
AZD2461; 1174043-16-3; AZD-2461; UNII-3K288XF5XJ; 3K288XF5XJ; AZD 2461; 4-(4-fluoro-3-(4-methoxypiperidine-1-carbonyl)benzyl)phthalazin-1(2H)-one; 4-[4-Fluoro-3-[(4-methoxypiperidin-1-yl)carbonyl]benzyl]phthalazin-1(2H)-one; 1(2H)-Phthalazinone, 4-[[4-fluoro-3-[(4-methoxy-1-piperidinyl)carbonyl]phenyl]methyl]-; 4-(4-Fluoro-3-((4-methoxypiperidin-1-yl)carbonyl)benzyl)phthalazin-1(2H)-one; 1(2H)-Phthalazinone, 4-((4-fluoro-3-((4-methoxy-1-piperidinyl)carbonyl)phenyl)methyl)-; HYNBNUYQTQIHJK-UHFFFAOYSA-N; SCHEMBL77012
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C00-D48; ICD-9: 140-199, 210-229] | Phase 1 | [1], [2] | |
| Company |
AstraZeneca
|
|||
| Structure |
 |
Download2D MOL
|
||
| Formula |
C22H22FN3O3
|
|||
| Canonical SMILES |
COC1CCN(CC1)C(=O)C2=C(C=CC(=C2)CC3=NNC(=O)C4=CC=CC=C43)F
|
|||
| InChI |
1S/C22H22FN3O3/c1-29-15-8-10-26(11-9-15)22(28)18-12-14(6-7-19(18)23)13-20-16-4-2-3-5-17(16)21(27)25-24-20/h2-7,12,15H,8-11,13H2,1H3,(H,25,27)
|
|||
| InChIKey |
HYNBNUYQTQIHJK-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1174043-16-3
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8472). | |||
| REF 2 | ClinicalTrials.gov (NCT01247168) An Open-Label, Dose-Escalation Study of AZD2461. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.